Quick Answer
Polaryx Therapeutics, Inc. reported Net Income of -$8.98 million for fiscal year 2025.
Polaryx Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$8.98M +70.4% |
-$30.36M | — |
| Diluted EPS | -$0.20 +77.5% |
-$0.89 | — |
| Total Assets | $5.17M +3.4% |
$5.00M | — |
| Cash and Equivalents | $5.14M +11.3% |
$4.62M | — |
| Stockholders Equity | $4.57M -3.1% |
$4.71M +269.0% |
$1.28M |
| R&D Expense | $6.27M +122.9% |
$2.81M | — |
| Operating Income | -$7.82M -79.7% |
-$4.35M | — |
| Shares Outstanding | 47.34M +15.0% |
41.15M | — |
- Polaryx Therapeutics, Inc. reported Net Income of -$8.98 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +70.4% in Net Income compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Diluted EPS of $0.20 per share (loss) for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +77.5% in Diluted EPS compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Total Assets of $5.17 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +3.4% in Total Assets compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Cash and Equivalents of $5.14 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +11.3% in Cash and Equivalents compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Stockholders Equity of $4.57 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed a decrease of -3.1% in Stockholders Equity compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported R&D Expense of $6.27 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +122.9% in R&D Expense compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Operating Income of -$7.82 million for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed a decrease of -79.7% in Operating Income compared to the prior fiscal year.
- Polaryx Therapeutics, Inc. reported Shares Outstanding of 47.34 million shares for fiscal year 2025.
- Polaryx Therapeutics, Inc. showed an increase of +15.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: